Composition
Tiloron 125.0 mg.
Excipients:
Core: potato starch - 46,000 mg, microcrystalline cellulose - 120,000 mg, povidone (povidone K30) - 3,000 mg, calcium stearate - 3,000 mg, croscarmellose (croscarmellose sodium) - 3,000 mg;
film coating: hypromellose (hydroxypropyl methylcellulose) - 6.8100 mg, titanium dioxide - 3.5630 mg, macrogol (polyethylene glycol-4000) - 0.9130 mg, polysorbate-80 (tween-80) - 0.1140 mg, quinoline yellow dye (E 104) - 0.2470 mg, sunset yellow dye (E 110) - 0.3530 mg.
pharmacotherapeutic group
antiviral immunostimulant - inducer of interferon formation
Pharmacodynamics
Low-molecular synthetic inducer of interferon, stimulating the formation of all types of interferons in the body (alpha, beta, gamma and lambda). The main producers of interferon in response to tylron administration are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral administration maximum production of interferon is determined in the sequence intestine - liver - blood in 4-24 hours. Amixin® has immunomodulatory and antiviral effect.
Experimental data on single oral administration of Amixin® in dose, equivalent to maximum daily dose for human, maximum concentration in lung tissue of interferon lambda is determined after 24 hours, interferon alpha - 48 hours. Induction of interferon lambda in the lung tissue enhances the antiviral protection of the respiratory tract in influenza and other respiratory viral infections.
In human leukocytes it induces the synthesis of interferon. It stimulates bone marrow stem cells, and, depending on the dose, enhances antibody production, reduces the degree of immunosuppression, restores the ratio of T-suppressors to T-helpers. Effective against various viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses. The mechanism of antiviral action is associated with inhibition of translation of virus-specific proteins in infected cells, resulting in inhibition of virus reproduction.
Pharmacokinetics .
After oral administration, it is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% of the drug is bound to plasma proteins. The drug is eliminated practically unchanged in intestine (70%) and kidney (9%). The elimination half-life (T1/2) is 48 hours. The drug is not biotransformed and does not accumulate in the body.
Indications
As part of complex therapy:
In children from 7 to 18 years:
- Treatment of influenza and other acute respiratory viral infections (ARI).
In adults:
- Treatment of influenza and other acute respiratory viral infections;
- Treatment of herpes infections.
Prevention of influenza and other acute respiratory infections in adults.
Contraindications .
-Hypersensitivity to Tyloron or any other component of the drug. Pregnancy and breast-feeding. Childhood age under 18 years.
Dosage and administration method
Amixin® is taken orally, after meals.
For children from 7 to 18 years:
In uncomplicated forms of influenza and other ARI - 60 mg once a day on the 1st, 2nd and 4th day from the beginning of treatment. The course dose is 180 mg (3 tablets).
For adults:
For treatment of influenza and other acute respiratory infections - 125 mg per day for the first 2 days of treatment, then 125 mg after 48 hours. For a course of 750 mg (6 tablets).
For prophylaxis of influenza and other acute respiratory viral infections - 125 mg once a week for 6 weeks. For a course of 750 mg (6 tablets).
For the treatment of herpes infections - the first two days with 125 mg, then after 48 hours with 125 mg. The course dose is 1.25-2.5 g (10-20 tablets).
During the treatment of influenza and other acute respiratory viral infections, consult a physician in the case of persistence of the disease symptoms for more than 4 days.
Side effects
Allergic reactions, dyspepsia, short-term chills may occur. If any of the side effects stated in the instructions worsen, or if you notice any other side effects not stated in the instructions, inform your doctor.
Overdose
Up to the present time, no cases of overdose of Amixin® have been reported.
Drug interaction
It is compatible with antibiotics and medicines of traditional treatment of viral and bacterial diseases. Clinically significant interaction of Amixin® with antibiotics and agents of traditional treatment of viral and bacterial diseases was not identified.
Special indications
Influence on the ability to drive vehicles and mechanisms
The drug does not affect the ability to drive vehicles and engage in other potentially dangerous activities that require high concentration and quick psychomotor reactions.
Storage temperature
2℃ to 25℃
Tiloron 125.0 mg.
Excipients:
Core: potato starch - 46,000 mg, microcrystalline cellulose - 120,000 mg, povidone (povidone K30) - 3,000 mg, calcium stearate - 3,000 mg, croscarmellose (croscarmellose sodium) - 3,000 mg;
film coating: hypromellose (hydroxypropyl methylcellulose) - 6.8100 mg, titanium dioxide - 3.5630 mg, macrogol (polyethylene glycol-4000) - 0.9130 mg, polysorbate-80 (tween-80) - 0.1140 mg, quinoline yellow dye (E 104) - 0.2470 mg, sunset yellow dye (E 110) - 0.3530 mg.
pharmacotherapeutic group
antiviral immunostimulant - inducer of interferon formation
Pharmacodynamics
Low-molecular synthetic inducer of interferon, stimulating the formation of all types of interferons in the body (alpha, beta, gamma and lambda). The main producers of interferon in response to tylron administration are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral administration maximum production of interferon is determined in the sequence intestine - liver - blood in 4-24 hours. Amixin® has immunomodulatory and antiviral effect.
Experimental data on single oral administration of Amixin® in dose, equivalent to maximum daily dose for human, maximum concentration in lung tissue of interferon lambda is determined after 24 hours, interferon alpha - 48 hours. Induction of interferon lambda in the lung tissue enhances the antiviral protection of the respiratory tract in influenza and other respiratory viral infections.
In human leukocytes it induces the synthesis of interferon. It stimulates bone marrow stem cells, and, depending on the dose, enhances antibody production, reduces the degree of immunosuppression, restores the ratio of T-suppressors to T-helpers. Effective against various viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses. The mechanism of antiviral action is associated with inhibition of translation of virus-specific proteins in infected cells, resulting in inhibition of virus reproduction.
Pharmacokinetics .
After oral administration, it is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% of the drug is bound to plasma proteins. The drug is eliminated practically unchanged in intestine (70%) and kidney (9%). The elimination half-life (T1/2) is 48 hours. The drug is not biotransformed and does not accumulate in the body.
Indications
As part of complex therapy:
In children from 7 to 18 years:
- Treatment of influenza and other acute respiratory viral infections (ARI).
In adults:
- Treatment of influenza and other acute respiratory viral infections;
- Treatment of herpes infections.
Prevention of influenza and other acute respiratory infections in adults.
Contraindications .
-Hypersensitivity to Tyloron or any other component of the drug. Pregnancy and breast-feeding. Childhood age under 18 years.
Dosage and administration method
Amixin® is taken orally, after meals.
For children from 7 to 18 years:
In uncomplicated forms of influenza and other ARI - 60 mg once a day on the 1st, 2nd and 4th day from the beginning of treatment. The course dose is 180 mg (3 tablets).
For adults:
For treatment of influenza and other acute respiratory infections - 125 mg per day for the first 2 days of treatment, then 125 mg after 48 hours. For a course of 750 mg (6 tablets).
For prophylaxis of influenza and other acute respiratory viral infections - 125 mg once a week for 6 weeks. For a course of 750 mg (6 tablets).
For the treatment of herpes infections - the first two days with 125 mg, then after 48 hours with 125 mg. The course dose is 1.25-2.5 g (10-20 tablets).
During the treatment of influenza and other acute respiratory viral infections, consult a physician in the case of persistence of the disease symptoms for more than 4 days.
Side effects
Allergic reactions, dyspepsia, short-term chills may occur. If any of the side effects stated in the instructions worsen, or if you notice any other side effects not stated in the instructions, inform your doctor.
Overdose
Up to the present time, no cases of overdose of Amixin® have been reported.
Drug interaction
It is compatible with antibiotics and medicines of traditional treatment of viral and bacterial diseases. Clinically significant interaction of Amixin® with antibiotics and agents of traditional treatment of viral and bacterial diseases was not identified.
Special indications
Influence on the ability to drive vehicles and mechanisms
The drug does not affect the ability to drive vehicles and engage in other potentially dangerous activities that require high concentration and quick psychomotor reactions.
Storage temperature
2℃ to 25℃
Related Products
